

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Synthesis of a New Analog of Thymidine for *In Vivo* Non-radioactive Labeling of DNA

Ch. Rodríguez-Tanty<sup>a</sup>; R. Pérez<sup>a</sup>; J. Miranda<sup>b</sup>; H. Vélez-Castro<sup>a</sup>; A. Rosado<sup>a</sup>; A. Macias<sup>a</sup>; L. Galán<sup>a</sup>; D. Higginson-clarke<sup>b</sup>; A. M. Riverón<sup>b</sup>

<sup>a</sup> Organic Chemistry Department, National Center for Scientific Research, Havana, Cuba <sup>b</sup> Molecular Biology Department, National Center for Scientific Research, Havana, Cuba

**To cite this Article** Rodríguez-Tanty, Ch. , Pérez, R. , Miranda, J. , Vélez-Castro, H. , Rosado, A. , Macias, A. , Galán, L. , Higginson-clarke, D. and Riverón, A. M.(1999) 'Synthesis of a New Analog of Thymidine for *In Vivo* Non-radioactive Labeling of DNA', Nucleosides, Nucleotides and Nucleic Acids, 18: 4, 1113 — 1117

**To link to this Article:** DOI: 10.1080/15257779908041663

**URL:** <http://dx.doi.org/10.1080/15257779908041663>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS OF A NEW ANALOG OF THYMIDINE FOR *IN VIVO* NON-RADIOACTIVE LABELING OF DNA

Ch. Rodríguez-Tanty<sup>1\*</sup>, R. Pérez<sup>1</sup>, J. Miranda<sup>2</sup>, H. Vélez-Castro<sup>1</sup>, A. Rosado<sup>1</sup>, A. Macías<sup>1</sup>, L. Galán, D. Higginson-Clarke<sup>2</sup>, A.M. Riverón<sup>2</sup>.

<sup>1</sup>Organic Chemistry Department, <sup>2</sup>Molecular Biology Department, National Center for Scientific Research, PO Box 6880, Havana, Cuba.

**ABSTRACT:** The introduction of 6-(*p*-bromobenzoylamino)caproyl radical in the methyl group of 2'-*O*-deoxythymidine is described. *In vivo* incorporation of this nucleoside to DNA was determined using a monoclonal antibody that recognized the radical.

Immunochemical labels have been successfully introduced at the base position of nucleosides <sup>1-8</sup>; however, they have never been introduced in the methyl group of thymidine. Here, we describe a procedure for synthesizing 5-{*N*-[caproyl-6-(*p*-bromobenzamine)]aminomethyl}-2'-*O*-deoxyuridine (**2**), which contains 6-(*p*-bromobenzamine)caproyl (BLC)<sup>7</sup> in the methyl group of thymidine. Results of *in vivo* DNA labeling using this new nucleoside are also discussed.


### RESULTS AND DISCUSSION

**Chemical Discussion:** Compound **2** was synthesized in six steps (*scheme 1*) and three of them (bromination, azidation and deacylation) were done in one pot. The intermediate **3** was prepared from **2** (*scheme 1*) as reported<sup>9</sup>, but modifying the purification step (see Experimental). Further, the azide anion displaced the bromine atom of **3**, and finally, the acetyl groups were removed from **4**. The overall yield of product **5**, starting from **2** was 36 %. Azide group of **5** was reduced according to Knouzi<sup>10</sup>. The structure of compounds

5 and 6 were determined using IR,  $^1\text{H}$ -,  $^{13}\text{C}$ -NMR and FAB-MS spectra. Finally, to obtain compound 7, the 6 was treated with 6-(*p*-bromobenzoylamino)caproic acid *N*-hydroxysuccinimide <sup>7,8</sup>. IR; NMR; FAB-MS and quantitative elemental analysis were used to characterize 7.

**Biological Discussion.** *In vivo* incorporation of modified thymidine to DNA can be done efficiently using Thy<sup>-</sup> mutants (cells lacking the ability of endogenous thymidine synthesis) and adding to the growth medium the nucleoside analog. A direct competitive ELISA determined *in vivo* incorporation of 7 to nuclear *Escherichia coli* (Thy<sup>-</sup>) DNA. Previous to the ELISA, labeled DNA molecules were hydrolyzed by using DNAase, and further, free modified nucleotides and the immobilized hapten compete for capturing the MAb. To estimate the nucleotide concentrations, the recorded absorbances were replaced in a previously obtained calibration curve. The calibration curve,  $\text{Abs} = b_2 + (b_1 - b_2) / [1 + (\text{nucl.conc}/b_3)^{b_4}]$  <sup>11</sup> (Eq. 1), had  $b_1 = 9.05571 \times 10^{-2}$ ,  $b_2 = 2.32773$ ,  $b_3 = 9.48242 \times 10^{-8}$  and  $b_4 = 1.86328$ . In three independent labeling experiments, 1  $\mu\text{g}$  of DNA was isolated, and their absorbances in the ELISAs were 0.262, 0.262 and 0.292, resulting in  $2.49 \times 10^{-8}$  M,  $2.49 \times 10^{-8}$  M and  $2.74 \times 10^{-8}$  M nucleotide concentration, respectively. These concentrations indicate that nearly 0.05 % of thymidine was replaced by the analog during DNA synthesis.

**EXPERIMENTAL. Chemical Synthesis.** All solvent were dried and stored as described <sup>7,8</sup>. Spectral measures were recorded as reported <sup>7,8</sup>. 5-Bromo 3', 5'-di-O-acetyl-2'-O-deoxythymidine (3): was obtaining from 3',5'-di-O-acetyl-2'-O-deoxythymidine<sup>12</sup>, as reported<sup>9</sup>. The product was isolated by removing the solvent *in vacuum*, and it was used without further purification in the next step. 5-Azido-2'-O-deoxythymidine (5): Sodium azide (1,19 g, 0,018 mol) was added to a solution of 3 (0,0092 mol) in dry acetonitrile (120 mL). When the reaction was over (checked by TLC), the solvent was removed, and the syrup (4) was dissolved in a solution of  $\text{NH}_3/\text{CH}_3\text{OH}$  (8 N) for removing the acetyl groups. The product was purified by column chromatography (chloroform:methanol, from 90:1 to 90:3). Yield: 36%, m.p.: 139-41 °C (lit<sup>13</sup> m.p.: 130-32 °C). IR: 3400s, 3050s, 2950s, 2150s ( $\nu\text{N}_3$ ), 1680s, 1460s, 1420s, 1280s, 1200m, 1100s, 1060s, 1000m, 960w, 880m, 760m, 660w.  $^1\text{H}$ -NMR (DMSO- $d_6$ ): 11,55 (1H, s, NH); 7,6 (1H, m, 6-CH); 6,16 (1H, t, 1'-CH); 5,8 (1H, s, 3'-OH); 5,05 (1H, s, 5'-OH); 4,25 (1H, s, 3'-CH); 4,05 (2H, s,  $\text{CH}_2\text{N}_3$ ); 3,8 (1H, s, 4'-CH); 3,55 (2H, s, 5'-CH<sub>2</sub>); 2,1 (2H, s, 2'-CH<sub>2</sub>).  $^{13}\text{C}$ -NMR (DMSO- $d_6$ ): 162,76 (c, 4-C'O); 150,08 (c, 2-C'O); 139,77 (t, 6-CH); 108,14 (c, 5-C'); 87,36 (t, 4'-CH); 84,15 (t, 1'-CH); 70,12 (t, 3'-CH); 61,11 (s, 5'-CH<sub>2</sub>); 46,78 (s,  $\text{CH}_2\text{N}_3$ ); 39,53 (s, 2'-CH<sub>2</sub>). FAB-MS ( $m/z$ ) = 284 ( $\text{M}+\text{H}$ )<sup>+</sup>. 5-Amino-2'-O-deoxythymidine (6): The synthesis was carried out according to the procedure for reducing azide group to amine group<sup>10</sup>. Yield: 74%, m.p.: 172-74 °C. IR: 3400s, 3050m, 2890m, 1660s, 1520s,



SCHEME 1

1480s, 1400m, 1360m, 1320m, 1280m, 1200w, 1100m, 1060m, 800w, 730w, 700w.  $^1\text{H-NMR}$  (DMSO- $\text{d}_6$ ): 7.75 (1H, s, NH); 7.6 (1H, m, 6-CH); 6.2 (1H, t, 1'-CH); 5.5-4.5 (4H, m, 5'-OH + 3'-OH +  $\text{NH}_2$ ); 4.25 (1H, s, 3'-CH); 3.68 (1H, a, 4'-CH); 3.6-3.5 (4H, 5'- $\text{CH}_2$  +  $\text{CH}_2\text{NH}$ ); 2.14 (2H, s, 2'- $\text{CH}_2$ ).  $^{13}\text{C-NMR}$  (DMSO- $\text{d}_6$ ): 163.19 (c, 4-CO); 150.31 (c, 2-CO); 135.89 (t, 6-CH); 115.51 (c, 5-C); 87.23 (t, 4'-CH); 83.79 (t, 1'-CH); 70.36 (t, 3'-CH); 61.29 (s, 5'- $\text{CH}_2$ ); 39.29 (s, 2'- $\text{CH}_2$ ); 38.37 (s,  $\text{CH}_2\text{NH}_2$ ). FAB-MS ( $m/z$ ) = 258 ( $\text{M}+\text{H}$ ) $^+$ . 5-{*N*-[caproyl-6-(*p*-bromobenzamine)] aminomethyl}-2'-*O*-deoxyuridine (**7**): The compound was synthesized as described<sup>7,8</sup>. Yield: 41%, m.p.: 200-02 °C. IR: 3420s, 2940w, 2860w, 1720m, 1660s, 1640s, 1540w, 1480w, 1400w, 1280m, 1100w, 1060w, 800w, 760w.  $^1\text{H-NMR}$  (DMSO- $\text{d}_6$ ): 11.38 (1H, s, NH); 8.51 (1H, s, 3-NH); 8.1 (1H, s, 2-NH); 7.8-7.65 (5H, m, *p*-BrBz + 6-CH); 6.2 (1H, t, 1'-CH); 5.26 (1H, s, 3'-OH); 4.95 (1H, s, 5'-OH); 4.25 (1H, s, 3'-CH); 3.94-3.73 (3H, m, 4'-CH + 5'- $\text{CH}_2$ ); 3.51 (2H, s,  $\text{CH}_2\text{NHCO}$ ); 3.29-3.2 (2H, q,  $\text{CH}_2\text{NHBz-}p\text{-Br}$ ); 2.18-1.99 (4H, m, 2'- $\text{CH}_2$  +  $\text{NHCOCH}_2$ ); 1.6-1.42 and 1.38-1.16 (6H, m, 3  $\text{CH}_2$ ).  $^{13}\text{C-NMR}$  (DMSO- $\text{d}_6$ ): 172.17 (c,  $\text{NHCOCH}_2$ ); 165.03 (c, 4-CO); 162.69 (c, *p*-BrBz-CO); 150.14 (c, 2-CO); 137.37 (t, 6-CH); 133.67 (c,  $\text{C}_{\text{arom-CO}}$ ); 131.14 and 129.18 (2 t,  $\text{C}_{\text{arom}}$ ); 124.61 (c,  $\text{C}_{\text{arom-Br}}$ ); 110.87 (c, 5-C); 87.35 (t, 4'-CH); 83.98 (t, 1'-CH); 70.46 (t, 3'-CH); 61.41 (s, 5'- $\text{CH}_2$ ); 39.41 (s, 2'- $\text{CH}_2$ ); 39.07(2); 38.74 (3s, 2  $\text{CH}_2\text{NHCO}$  +  $\text{NHCOCH}_2$ ); 28.75; 26.11 and 24.84 (3 s, 3  $\text{CH}_2$ ). FAB-MS  $m/z$  = 554 ( $\text{M}+\text{H}$ ) $^+$ . Anal. Calcd. for  $\text{C}_{23}\text{H}_{29}\text{N}_4\text{O}_7\text{Br}$ : C, 49.93; H, 5.24; N, 10.12; Br, 14.44. Found: C, 49.34; H, 5.13; N, 9.98.

**Biological Procedures. Bacterial Strains:** *Escherichia coli* cells (DH5 $\alpha$ )  $\text{Thy}^-$  mutants were obtained as described<sup>14</sup>. **In vivo DNA Labelling:**  $\text{Thy}^-$  cells were grown in LB medium alone, and in LB supplemented with 200  $\mu\text{g/mL}$  of **7** or thymidine. The cultures were shaken overnight at 37 °C. Phenylmethylsulfonylfluoride was added to cell lysate for protecting the BLC peptic bond from protease attack. Nuclear DNA molecules were obtained as reported<sup>15</sup>. **ELISA.** To measure the incorporation of the modified nucleotide **8** to DNA we designed a direct competitive ELISA<sup>8</sup>. The MAb and gelatin-hapten conjugate<sup>8</sup> optimum amounts, for coating the wells, were determined. To obtain a calibration curve, the concentration of free nucleoside was varied to attain the function relating absorbance with nucleotide concentration. The absorbance obtained in the competitive ELISA of hydrolyzed labeled DNA was used to estimate in the calibration curve the incorporation of thymidine analog to DNA. The experimental details in the direct competitive ELISA were described in a previous paper<sup>8</sup>. **Statistical method to estimate the incorporation of the modified nucleotide to DNA.** The function describing the relationship between the absorbances and known free nucleoside concentrations was fitted to a sigmoidal curve according to described<sup>11</sup>. Solving this equation for the absorbances obtained in the ELISA, we estimated the thymidine analog concentration. The equation was solved using an iterative method (ref).

## REFERENCES

- 1 Roget, A.; Teoule, R.; Bazin, H., *Nucleic Acids Research* **1989**, *17*, 7643.
- 2 Kessler, Ch.; Mühlegger, K.; Huber, E.; von der Eltz, H.; Rüger, R., *Biol. Chem. Hoppe-Seyler* **1990**, *371*, 953.
- 3 Singh, D.; Kumar, V.; Ganesh, K. N., *Nucleic Acids Research* **1990**, *18*, 3339.
- 4 Cook, A. F.; Vuocolo, E.; Brakel, Ch. L., *Nucleic Acids Research* **1988**, *16*, 4077.

- 5 Gibson, K. J.; Benkovics, S. J., *Nucleic Acids Research* **1987**, 15, 6455.
- 6 Safarti, S.R.; Pochet, S.; Guerreiro, C.; Namame, A.; Huynh-Dinh, T.; Igolen, J., *Tetrahedron* **1987**, 43, 3491.
- 7.- Rodríguez-Tanty, Ch.; López-Canovas, L.; López-Braut, A.; Rivero, M.; Higginson, D.; Vélez, H.; Riverón, A.; Macías, A. *Nucleosides & Nucleotides* **1995**, 14, 219-228.
- 8.- Rodríguez-Tanty, C.; Higginson-Clarke, D.; Hernández, M.; Pérez, R.; Vélez, H.; Riverón-Rojas, A.; Macías-Cabrera, A. *Nucleosides & Nucleotides* **1997**, 16, 455-467
- 9.- Baerwolf, D.; Langen, P., *Nucleic Acid Chemistry* **1978**, vol.1, L. B. Townsend and R. S. Tipson, Wiley-Interscience, New York, 359.
- 10.- Knouzi, N.; Vaultier, M.; Carrié, R., *Bull. de la Société Chimique de France* **1985**, 5, 815.
- 11.- O'Connell, M. A.; Belanger, B. A.; Haaland, P. D., *Chemometrics and Intelligent Laboratory System* **1993**, 20, 97.
- 12.- Michelson, A. M.; Todd A. R., *J. Chem. Soc.* **1955**, 816.
- 13.- Kampf, A.; Shipchandler, M. T.; Pillar, C.; Wilson, R. S.; Mertes, M. P., *Nucleic Acid Chemistry*, **1978**, vol 1, L. B. Townsend y R. S. Tipson, Wiley-Interscience, New York , 381.
- 14.- Jeffres, H. Miller, *Experiments in Molecular Genetics*, Experiment 31- *Selection of Thy- Strains with Trimethoprim*, Cold Spring Harbor Laboratory **1972**, Cold Spring Harbor, New York, 218-220.
- 15.- Sambrook, J.; Fritsch E.F.; Maniatis, T. *Molecular Cloning, A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. **1989**.
- 16.- Demidovich, B. P.; Maron, I.A. *Computational Mathematics*, Mir Publishers Moscow, **1973**, 273.